DoH Policies screened during the period: 1 January 2024 – 31 March 2024
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Policy proposals that will underpin the Adoption Support Services (Transitional Arrangements) Regulations (Northern Ireland)
- Consent for Hospital Post-Mortem Examination (PME) HSC Regional Policy
- NICE Clinical Guideline NG233 - Otitis media with effusion in under 12s (updates and replaces CG60)
- NICE Clinical Guideline NG234 - Spinal metastases and metastatic spinal cord compression (updates and replaces CG75)
- NICE Clinical Guideline NG235 - Intrapartum care (updates and replaces CG190)
- NICE Clinical Guideline NG236 - Stroke rehabilitation in adults (updates and replaces CG162)
- NICE Clinical Guideline NG238 - Cardiovascular disease: risk assessment and reduction, including lipid modification (updates and replaces CG181)
- NICE Technology Appraisal TA755 - Risdiplam for treating spinal muscular atrophy (revised)
- NICE Technology Appraisal TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (partial review)
- NICE Technology Appraisal TA937 - Targeted-release budesonide for treating primary IgA nephropathy
- NICE Technology Appraisal TA942 - Empagliflozin for treating chronic kidney disease
- NICE Technology Appraisal TA943 - Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes
- NICE Technology Appraisal TA944 - Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer
- NICE Technology Appraisal TA946 - Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (review of TA693)
- NICE Technology Appraisal TA947 - Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
- NICE Technology Appraisal TA948 - Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
- NICE Technology Appraisal TA949 - Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over
- NICE Technology Appraisal TA950 - Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over
- NICE Technology Appraisal TA951 - Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
- NICE Technology Appraisal TA952 - Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations
- NICE Technology Appraisal TA954 - Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments